Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly overstating its competitive position and providing unrealistic financial guidance for 2025, leading to significant investor losses when the truth was revealed [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased LifeMD shares between May 7, 2025, and August 5, 2025 [1][2]. - Investors have until October 27, 2025, to seek appointment as lead plaintiff representatives [2]. - The complaint alleges that LifeMD did not disclose rising customer acquisition costs related to its RexMD platform and its promotion of obesity medications like Wegovy and Zepbound [3]. Group 2: Company Background - LifeMD, headquartered in New York, provides virtual medical services and prescription delivery [2]. - Berger Montague, the law firm representing the plaintiffs, has a long history in securities class action litigation, having served investors for over five decades [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of LifeMD, Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements about its competitive position and financial guidance during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint claims that during the class period from May 7, 2025, to August 5, 2025, LifeMD's defendants overstated the company's competitive position [1]. - It is alleged that the defendants were reckless in raising LifeMD's 2025 guidance without properly accounting for increasing customer acquisition costs in the RexMD segment and related to obesity treatment drugs like Wegovy and Zepbound [1]. - As a result, the statements made by the defendants regarding LifeMD's business, operations, and prospects were materially false and misleading [1]. Next Steps for Shareholders - Shareholders who purchased shares of LFMD during the specified timeframe are encouraged to register for the class action by October 25, 2025, to potentially become lead plaintiffs [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. Firm's Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit, fraud, and illegal business practices [3]. - The firm aims to ensure that companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - Teladoc Health's stock price increased by over 9.7% to $9.185, following a rare bullish comment from Citron Research, which reaffirmed confidence in the company's long-term potential [1] Company Summary - Teladoc has been focusing on digital healthcare and virtual consultations in recent years [1] - Despite a decline in stock price from the peak during the COVID-19 pandemic, analysts believe the company is poised for new growth opportunities [1] Industry Summary - The acceleration of digital transformation in healthcare insurance and corporate health plans is expected to benefit Teladoc [1]

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-8903 CLASS PERIOD: May 7, 2025 to August 5, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated LifeMD's competitive positio ...

NEW YORK, Oct. 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important October 27, 2025 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased LifeMD securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or c ...

Key Points Citron Research sees Teladoc as a bargain ready to rip higher, citing the end of this government shutdown as a bullish catalyst. While Citron's favorite catalyst seems questionable, Teladoc's bargain valuation might make it worth considering anyway. Teladoc has fallen 66% over three years and trades at just 0.66 times sales despite generating strong free cash flow. 10 stocks we like better than Teladoc Health › Bullish comments from a noted short-seller pushed shares of Teladoc Health ...

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In LifeMD (LFMD) To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in LifeMD between May 7, 2025 and August 5, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- What’s Happening: Bragar ...

Company Overview - LifeMD, Inc. is a leading provider of virtual primary care services, offering telemedicine, laboratory and pharmacy access, and specialized treatment for over 200 conditions [2] - The company utilizes a vertically integrated digital care platform, a 50-state affiliated medical group, a state-of-the-art compounding pharmacy, and a U.S.-based patient care center to enhance access to high-quality and affordable care [2] Recent Developments - LifeMD announced its participation in the ROTH 4 Annual Healthcare Opportunities Conference scheduled for October 9, 2025, in New York City [1] - Management will engage in one-on-one meetings with investors throughout the conference [1] - Investors interested in attending can register by contacting their ROTH Capital Partners representative [1]

Core Insights - RetinalGenix Technologies Inc. has made significant advancements in its patent portfolio, positioning itself at the forefront of home and remote health monitoring for ocular and systemic diseases [1][5] Patent Developments - Recently granted patents, including U.S. Patent Application No. 2024/0099581 Al, cover key aspects of real-time home and remote ocular monitoring and scalable physician alert systems [2] - The current patent focuses on expanding the mapping of the peripheral retina, which is crucial for identifying diseases such as early retinal changes associated with diabetes and biomarkers linked to Alzheimer's disease [3] Technology Integration - RetinalGenix's proprietary DNA/RNA/GPS Pharmaco-Genetic Mapping™ platform is planned to integrate with the high-resolution retinal imaging system, empowering patients and clinicians with actionable biomarker information [4] - The combination of these technologies aims to reduce the frequency of office visits and streamline critical care workflows across various settings, including homes and clinics [4] Market Positioning - The company's patents provide strong protection for device, system, and digital workflow innovations, setting it apart in the industry and positioning it for new partnerships and licensing opportunities [5][6] - The advancements are expected to enhance strategic competitive advantage and expand revenue generation opportunities in the telemedicine, ophthalmology, and healthcare technology sectors [6]

NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the expansion of its state-of-the-art affiliated pharmacy to include advanced non-sterile compounding capabilities for oral and topical medications. This milestone extends LifeMD’s pharmacy growth strategy by enabling its vertically integrated platform to deliver tailored therapies designed to meet evolving patient needs while improving efficiency and reducing relian ...